chronic hepatitis D
Hepatology · 2024–2025
3decisions
1medicine
3carried consumer input
0individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| bulevirtide Treatment of chronic hepatitis D (CHD) in patients positive for hepatitis D virus (HDV) RNA as detected by PCR. | Jul 2025 | Deferred | input received Hepatitis Australia · Liver Foundation |
| bulevirtide Treatment of chronic hepatitis D (CHD) in patients positive for hepatitis D virus (HDV) RNA as detected by PCR, with compensated liver disease and elevated… | Mar 2025 | Deferred | input received Hepatitis Australia · Liver Foundation |
| bulevirtide Treatment of chronic hepatitis D (CHD) in adult patients positive for hepatitis D virus (HDV) RNA as detected by PCR, with elevated serum alanine… | Mar 2024 | Not recommended | input received Hepatitis Australia |
Who spoke
Hepatitis Australia · Liver Foundation
Appraised elsewhere
NICE, in England and Wales, has appraised 1 technology for this condition, recommending 1 . A different committee, a different population and a different price: this is what has been looked at there, not a verdict on what happened here.
| Technology | Appraisal | Outcome | Date |
|---|---|---|---|
| bulevirtideBulevirtide for treating chronic hepatitis D | TA896 | recommended restricted | 2023-06 |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 3 of 3 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.